Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
4.
Eur J Clin Nutr ; 76(8): 1117-1124, 2022 08.
Article in English | MEDLINE | ID: mdl-35140313

ABSTRACT

BACKGROUND/OBJECTIVES: Routine use of vitamin D supplements has increased substantially in the United States. However, the safety and tolerability of long-term use of high-dose vitamin D are not known. We assessed the safety and tolerability of high-dose, daily vitamin D3 in the vitamin D and type 2 diabetes (D2d) study. SUBJECTS/METHODS: In total, 2423 overweight/obese persons with prediabetes were randomized in a double-blind manner to either 4000 IU of vitamin D3 (the tolerable upper intake level for adults by the National Academy of Medicine) taken daily or matching placebo. All participants were included in this analysis. Incident adverse events (AE) were ascertained 4 times a year at in-person visits (twice a year) and interim remote encounters (twice a year) and were defined as untoward or unfavorable medical occurrences. Serious adverse events (SAE) included death, life-threatening events, and hospitalizations. RESULTS: A total of 8304 AEs occurred during 3 years of follow-up and were less frequent in the vitamin D group compared to placebo (Incidence Rate Ratio [IRR] = 0.94; 95% Confidence Interval (CI) 0.90, 0.98). The overall frequency of protocol-specified AEs of interest, which included nephrolithiasis, hypercalcemia, hypercalciuria, or low estimated glomerular filtration rate, was low and did not differ by group. There were no significant between-group differences in total SAEs (IRR = 0.96 (0.81, 1.14)). CONCLUSION: Vitamin D3 supplementation at 4000 IU per day was safe and well tolerated among overweight/obese participants at high risk for diabetes who were appropriately monitored for safety. In this population, this dose of vitamin D3 did not increase risk of AEs or SAEs, including those previously associated with vitamin D such as hypercalcemia, hypercalciuria, or nephrolithiasis. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01942694, prospectively registered September 16, 2013.


Subject(s)
Diabetes Mellitus, Type 2 , Hypercalcemia , Nephrolithiasis , Prediabetic State , Adult , Cholecalciferol , Diabetes Mellitus, Type 2/drug therapy , Dietary Supplements/adverse effects , Double-Blind Method , Humans , Hypercalcemia/chemically induced , Hypercalcemia/drug therapy , Hypercalcemia/epidemiology , Hypercalciuria/chemically induced , Hypercalciuria/drug therapy , Nephrolithiasis/chemically induced , Nephrolithiasis/drug therapy , Obesity/drug therapy , Overweight/complications , Overweight/drug therapy , Prediabetic State/drug therapy , Vitamin D , Vitamins
9.
10.
J Diabetes Complications ; 31(2): 353-357, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27431890

ABSTRACT

AIMS: Determine the prevalence of glucocorticoid use in U.S. adults with diabetes and whether prevalence is associated with reduced skeletal health, as measured by fracture history and bisphosphonate use. METHODS: Participants were age≥20years from the cross-sectional National Health and Nutrition Examination Survey (1999-2010; N=15,661). Diabetes was determined by self-report, fasting plasma glucose ≥126mg/dL (≥6.99mmol/L), or A1c ≥6.5% (≥47.5mmol/mol) (n=4539). Prevalences of fractures and bisphosphonate use were determined by diabetes status and glucocorticoid use. Logistic regression was stratified by sex and assessed the effect of glucocorticoid use and diabetes associated with fractures and bisphosphonates. RESULTS: The age-standardized prevalence of glucocorticoid use was higher among persons with diabetes (3.2% vs. 2.0% without diabetes, p=0.001). Among adults with diabetes, the prevalence of fractures was significantly higher among those taking glucocorticoids vs. those not (38.3% vs. 26.1%, p=0.048). The prevalences of fractures and bisphosphonate use were generally similar in those with and without diabetes when stratified by glucocorticoid use. In logistic regression analysis among men, the combination of diabetes and glucocorticoid use (compared to those with neither) was highly associated with bisphosphonate use, while adjusting for demographic factors. Among women, having diabetes and glucocorticoid use increased the odds of fractures, while adjusting for demographic factors and menopause. CONCLUSIONS: The prevalence of fractures was greater for those with diabetes taking glucocorticoids versus those not taking glucocorticoids. This study provides a national framework for further research on elucidating these associations.


Subject(s)
Bone and Bones/drug effects , Diabetes Complications/chemically induced , Glucocorticoids/adverse effects , Osteoporosis/chemically induced , Osteoporotic Fractures/etiology , Adult , Aged , Bone Density Conservation Agents/therapeutic use , Cross-Sectional Studies , Diabetes Complications/drug therapy , Diabetes Complications/epidemiology , Diphosphonates/therapeutic use , Female , Humans , Logistic Models , Male , Middle Aged , Nutrition Surveys , Osteoporosis/complications , Osteoporosis/drug therapy , Osteoporosis/epidemiology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/prevention & control , Risk , Self Report , Sex Factors , United States/epidemiology
11.
BMC Endocr Disord ; 12: 5, 2012 May 30.
Article in English | MEDLINE | ID: mdl-22646230

ABSTRACT

BACKGROUND: Hypoglycemia is a common complication of diabetes treatment. This paper describes symptoms, predecessors, consequences and medications associated with the first episode of severe hypoglycemia among ACCORD participants with type 2 diabetes, and compares these between intensive (Int: goal A1C <6.0%) and standard (Std, goal A1C 7-7.9%) glycemia intervention groups. METHODS: Information about symptoms, antecedents, and consequences was collected at the time participants reported an episode of severe hypoglycemia. Data on medications prescribed during the clinical trial was used to determine the association of particular diabetes drug classes and severe hypoglycemia. RESULTS: The most frequently reported symptoms in both glycemia group were weakness/fatigue (Int 29%; Std 30%) and sweating (Int 26%; Std 27%), followed by confusion/disorientation (Int 22%; Std 29%) and shakiness (Int 21%; Std 19%). Approximately half of all events were preceded by a variation in food intake (Int 48%; Std 58%). The most common consequences were confusion (Int 37%; Std 34%), loss of consciousness (Int 25%; Std 25%), and hospitalization (Int 18%; Std 24%). The highest rates of hypoglycemia were found among those participants treated with insulin only (Int 6.09/100 person yrs; Std 2.64/100 person yrs) while the lowest were among those prescribed oral agents only (Int 1.93/100 person yrs; Std 0.20/100 person yrs). CONCLUSIONS: Severe hypoglycemia episodes were frequently preceded by a change in food intake, making many episodes potentially preventable. Symptoms of confusion/disorientation and loss of consciousness were frequently seen. The highest rates of hypoglycemia were seen with prescription of insulin, either alone or in combination with other medications. CLINICAL TRIAL REGISTRATION: Number: NCT00000620.

13.
Arq. bras. endocrinol. metab ; 55(8): 669-669, nov. 2011.
Article in English | LILACS | ID: lil-610472

ABSTRACT

Although common themes permeate the environment across continents and particular divergences as to how to proceed exist between different regulatory agencies, it seems that policies are still in flux. Not all polices will suffice to fit all dissimilar biologics, and these in place or being developed may, in turn, change to accommodate new or unexpected developments. Consideration for accelerated approval for those compounds that do not present complex questions should be considered.The regulatory agencies should be more forthcoming, the industry sector exercise social responsibility, and the public should have realistic expectations.


Embora haja temas comuns no ambiente dos diferentes continentes e divergências particulares sobre como proceder entre diferentes agências regulatórias, parece que as decisões políticas ainda caminham. Nem todas as políticas serão suficientes para acomodar todos os diferentes produtos biológicos, e as políticas atuais ou em desenvolvimento podem, por sua vez, mudar para acomodar novos e inesperados desenvolvimentos. Deve-se considerar a aprovação mais rápida para aqueles compostos que não apresentem questões complexas. As agências regulatórias deveriam ser mais acessíveis, as indústrias deveriam exercitar sua responsabilidade social e o público deveria ter expectativas realísticas.


Subject(s)
Child , Humans , Biosimilar Pharmaceuticals/pharmacokinetics , Legislation, Drug/standards , Biosimilar Pharmaceuticals/chemistry , Europe , Therapeutic Equivalency , United States
14.
J Clin Endocrinol Metab ; 96(6): 1587-609, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21602453

ABSTRACT

OBJECTIVE: The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails. An initial draft was prepared by the Task Force, with the help of a medical writer, and reviewed and commented on by members of The Endocrine Society. A second draft was reviewed and approved by The Endocrine Society Council. At each stage of review, the Task Force received written comments and incorporated substantive changes. CONCLUSIONS: GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks associated with GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.


Subject(s)
Dwarfism, Pituitary/diagnosis , Dwarfism, Pituitary/therapy , Hormone Replacement Therapy , Human Growth Hormone/therapeutic use , Adult , Evidence-Based Medicine , Human Growth Hormone/deficiency , Humans
15.
Arq Bras Endocrinol Metabol ; 55(8): 669, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22218453

ABSTRACT

Although common themes permeate the environment across continents and particular divergences as to how to proceed exist between different regulatory agencies, it seems that policies are still in flux. Not all policies will suffice to fit all dissimilar biologics, and these in place or being developed may, in turn, change to accommodate new or unexpected developments. Consideration for accelerated approval for those compounds that do not present complex questions should be considered.The regulatory agencies should be more forthcoming, the industry sector exercise social responsibility, and the public should have realistic expectations.


Subject(s)
Biosimilar Pharmaceuticals/pharmacokinetics , Legislation, Drug/standards , Biosimilar Pharmaceuticals/chemistry , Child , Europe , Humans , Therapeutic Equivalency , United States
19.
Diabetes Care ; 33(5): 983-90, 2010 May.
Article in English | MEDLINE | ID: mdl-20427682

ABSTRACT

OBJECTIVE: Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251 with mean age 62 years, median duration of diabetes 10 years, and median A1C 8.1%) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0-7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models. RESULTS: Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6-9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%. CONCLUSIONS: These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/mortality , Glycated Hemoglobin/metabolism , Hypoglycemic Agents/therapeutic use , Aged , Cause of Death , Female , Follow-Up Studies , Humans , Hyperglycemia/drug therapy , Hyperglycemia/mortality , Male , Middle Aged , Multivariate Analysis , Risk Factors
20.
Horm Res ; 72(3): 167-71, 2009.
Article in English | MEDLINE | ID: mdl-19729948

ABSTRACT

BACKGROUND: Fifteen percent of small for gestational age (SGA) children remain short and undergo thyroid axis evaluations. METHODS: We analyzed data on thyroid assessment of 58 SGA children. Five had primary autoimmune hypothyroidism. In the remaining 53 patients, TSH, free T4 (FT4), antithyroid antibodies and 90-min TRH test results were analyzed. Patients were grouped into G1 (n = 27; normal) and G2 (n = 26; abnormal) according to their response to the TRH test compared with 30 normal children. RESULTS: No differences were found in chronological age, gestational age, or birth weight standard deviation score (SDS) between groups. G2 showed higher SDS BMI at consultation (p < 0.05). FT4 (ng/dl) levels were similar in all groups, while basal TSH levels were statistically different in G2 compared with G1 and controls. In 21 G2 patients treated with thyroxine, FT4 levels did not change, TSH normalized, BMI SDS and height remained unchanged. CONCLUSION: These data suggest that in SGA short children thyroid abnormalities may occur. Some of them may be due to a different setting of the hypothalamic-hypophyseal-thyroid axis during intrauterine life. Intrauterine growth retardation may permanently influence endocrine systems by affecting their programming during development. Further follow-up is needed to confirm these findings and to assess their natural history and potential clinical impact.


Subject(s)
Growth Disorders/drug therapy , Hypothalamo-Hypophyseal System/physiology , Infant, Small for Gestational Age/growth & development , Thyrotropin/blood , Adolescent , Autoimmunity , Body Height , Child , Child, Preschool , Female , Humans , Infant, Newborn , Male , Thyroid Gland/immunology , Thyrotropin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...